Cargando…

Uterine carcinosarcoma: A 10-year single institution experience

OBJECTIVE: This study aimed to determine 5-year progression-free and overall survival in patients with uterine carcinosarcoma, to determine clinical and surgical-pathologic features, to recognize patterns of recurrence and to identify prognostic factors influencing progression-free survival (PFS) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terblanche, Leana, Botha, Matthys H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302809/ https://www.ncbi.nlm.nih.gov/pubmed/35862371 http://dx.doi.org/10.1371/journal.pone.0271526

Ejemplares similares

Uterine carcinosarcomas: 8-year single center experience of 25 cases
por: Dave, Kalpana S., et al.
Publicado: (2011)

Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

Racial and Ethnic Disparities in Gynecologic Carcinosarcoma: A Single-Institution Experience
por: Mercado, Kristina E., et al.
Publicado: (2023)

Trends of uterine carcinosarcoma in the United States
por: Matsuo, Koji, et al.
Publicado: (2018)

Targeting the TGFβ pathway in uterine carcinosarcoma
por: Dwivedi, Shailendra Kumar Dhar, et al.
Publicado: (2020)

Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
por: Sertier, Anne-Sophie, et al.
Publicado: (2023)

Role of TGF-β signaling in uterine carcinosarcoma
por: Dhar Dwivedi, Shailendra Kumar, et al.
Publicado: (2015)

Identification of distinct molecular subtypes of uterine carcinosarcoma
por: An, Yang, et al.
Publicado: (2017)

Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience
por: Nizam, Aaron, et al.
Publicado: (2019)

Uterine Carcinosarcoma in a Patient with Didelphys Uterus
por: Iavazzo, C., et al.
Publicado: (2013)

The prognostic significance of the heterologous component in uterine carcinosarcomas
por: Can, Behzat, et al.
Publicado: (2023)

The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas
por: Moukarzel, Lea A., et al.
Publicado: (2021)

Fatal pulmonary thromboembolism associated with uterine carcinosarcoma
por: Lodetti, Giorgia, et al.
Publicado: (2023)

Influence of Clinical and Surgical Factors on Uterine Carcinosarcoma Survival
por: Gracia, Myriam, et al.
Publicado: (2023)

Brain Metastasis in a Young Patient with Uterine Carcinosarcoma
por: Katiyar, Vatsala, et al.
Publicado: (2019)

Uterine Carcinosarcoma: A Case Report and Literature Review
por: Kord, Ali, et al.
Publicado: (2020)

Which is worse: uterine papillary serous carcinomas or carcinosarcomas?
por: Song, Taejong, et al.
Publicado: (2011)

In‐depth molecular profiling of the biphasic components of uterine carcinosarcomas
por: McConechy, Melissa K, et al.
Publicado: (2015)

Prognostic value of the TCGA molecular classification in uterine carcinosarcoma
por: Travaglino, Antonio, et al.
Publicado: (2021)

Clinical utility of CA-125 in the management of uterine carcinosarcoma
por: Matsuo, Koji, et al.
Publicado: (2018)

The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Uterine Carcinosarcoma in a 2-year-old Female Wistar Hannover GALAS Rat
por: Takami, Shigeaki, et al.
Publicado: (2011)

Clostridium and Bacteroides bacteremia as initial presentation of uterine carcinosarcoma
por: Imo, Chinonye S., et al.
Publicado: (2022)

Carcinosarcoma of the uterine cervix arising from Müllerian ducts
por: Kim, Myounghwan, et al.
Publicado: (2015)

Port-Site Metastasis of Uterine Carcinosarcoma after Laparoscopy
por: Tan, Zhen, et al.
Publicado: (2017)

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
por: McNamara, Blair, et al.
Publicado: (2023)

Inter-component immunohistochemical assessment of proliferative markers in uterine carcinosarcoma
por: Pyra, Andrzej, et al.
Publicado: (2022)

Management and Prognosis of Patients with Recurrent or Persistent/Progressive Uterine Carcinosarcoma
por: Tung, Hsiu-Jung, et al.
Publicado: (2022)

OSucs: An Online Prognostic Biomarker Analysis Tool for Uterine Carcinosarcoma
por: An, Yang, et al.
Publicado: (2020)

Uterine carcinosarcoma associated with a germline nibrin (NBN) mutation
por: Markert, Tahireh, et al.
Publicado: (2022)

Pure abscopal effect in a patient with advanced uterine carcinosarcoma
por: Okamoto, Kazuhiro, et al.
Publicado: (2023)

The influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma
por: Park, Hae Jin, et al.
Publicado: (2011)

Adjuvant Treatment Modalities, Prognostic Predictors and Outcomes of Uterine Carcinosarcomas
por: Gungorduk, Kemal, et al.
Publicado: (2015)

Cancer antigen 125 is associated with disease status in uterine carcinosarcoma
por: Ross, Malcolm Strachan, et al.
Publicado: (2019)

Clinically aggressive “low-grade” uterine carcinosarcoma: A case report
por: Clearman, Theresa, et al.
Publicado: (2015)

Non-islet cell tumor hypoglycemia in a patient with uterine carcinosarcoma
por: Singleton, Miller P., et al.
Publicado: (2021)

Feline uterine carcinosarcoma infiltrated with osteoclast-like giant cells
por: MURAKAMI, Mami, et al.
Publicado: (2022)

Role of MRI in uterine didelphys with co-existing endometrial carcinosarcoma
por: McGregor, Jill, et al.
Publicado: (2018)

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives
por: Vitale, Salvatore Giovanni, et al.
Publicado: (2017)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
por: Hunt, Jonathan T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fm7jq37u4pb6lvnq72olcrrfep